To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Agriculture.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H693B153EA9ED407ABD4B759E40CB75A9: 1. Short title This Act may be cited as the Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023.
- Section H8590D66BD1F745B3BA115AF5A0550F49: 2. Expanding tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis Section 524(a)(3) of the...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
This bill, To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Agriculture
Primary Purpose
This bill, To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
Contextual inference, no direct clause citation- health care providers and patients
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- federal implementing agencies
- health care providers and patients
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMr. Schweikert (for himself, Mr. McCarthy, Mr. Burgess, Mr. Self, …
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "federal_implementing_agencies"
- → Federal agencies assigned duties by the bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology